Processa PharmaceuticalsPCSA
13F holders, Q2 2024 (June 30)9holders −2
1new positions
3sold out
$2.24avg. 13F price*
At the end of Q2 2024, 9 institutions reported holding Processa Pharmaceuticals Inc. (PCSA) in their 13F filings, down 2 from Q1 2024. 1 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($55K), Geode Capital Management, LLC ($39K) and Tower Research Capital LLC (TRC) ($7K).
- Company
- Processa Pharmaceuticals Inc.
- CUSIP
- 74275C304
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $39K |
| Exits | 3 | $182K |
All 13F filers, Q1 2024 → Q2 2024: 17,237 shares bought and 78,539 shares sold, net −61,302 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Vanguard Group Inc. | 0.00% | No change | 24,433 | $55K |
| Geode Capital Management, LLC | 0.00% | New | 17,237 | $39K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -33.4% | 2,999 | $7K |
| Wells Fargo & Company | 0.00% | Reduce -9.4% | 154 | $345 |
| Main Street Group, LTD | 0.00% | No change | 100 | $209 |
| Allworth Financial LP | 0.00% | No change | 85 | $139 |
| Bank of America Corp. | 0.00% | Reduce -86.9% | 21 | $47 |
| Macroview Investment Management LLC | 0.00% | No change | 1 | $3 |
| Royal Bank of Canada | 0.00% | No change | 4 | $0 |
"% of holder's portfolio" is PCSA's weight in each manager's 13F, not the share of Processa Pharmaceuticals Inc. the manager owns.